Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has formed a strategic partnership with Microport in connection with a $43.4m round.

Medical device manufacturer MicroPort Scientific led a €40m ($43.4m) series C round yesterday for Robocath, the France-based developer of a cardiovascular disease treatment system.

The round included Luxembourg CLIIF, an investment fund managed by the Tsinghua University-affiliated TUS-Holdings, as well as regional investment vehicles Go Capital, NCI and Normandie Participations, and national investment funds M Capital and Supernova Invest.

Financial services firm Crédit Agricole’s Unexo and Crédit Agricole Normandie units filled out the round with investment firms CS Group and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.